Practical and ethical issues in the development of a vaccine against Schistosomiasis mansoni

American Journal of Tropical Medicine and Hygiene

Volumn 66, Issue 4, 2002, Pages 348-358

  Todd, Charles W ^a   Colley, Daniel G ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCHISTOSOMA VACCINE;

ADJUVANT THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; FINANCIAL MANAGEMENT; HUMAN; IMMUNIZATION; IMMUNOPATHOLOGY; PHASE 3 CLINICAL TRIAL; REVIEW; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SEROLOGY;

SCHISTOSOMA; SCHISTOSOMA MANSONI; TREMATODA;

EID: 0036330433     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.66.348     Document Type: Review

References (101)

1. Progress in vaccine development
2. Schistosomiasis: Forty years' war on the worm
3. The search for a vaccine against schistosomiasis: A difficult but an achievable goal
4. Schistosomiasis vaccines: Research to development
5. Schistosomiasis vaccines: A devils advocate view
6. Schistosomiasis vaccines: A response to a devil's advocate's view
7. Antischistosomal vaccines: Beyond the laboratory
8. Field evaluation of vaccine efficacy
9. Assessing vaccine efficacy in the field
10. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission
11. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization
12. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic
13. Differences in adult Schistosoma mansoni worm burden requirements for the establishment of resistance to reinfection in inbred mice. I. CBA/J and C57BL/6 mice
14. A quantitative post-mortem study of schistosomiasis mansoni in man
15. Comparison of irradiated cercariae schistosome vaccine models that use 15- and 50-kilorad doses: The 15-kilorad dose gives greater protection, smaller liver sizes, and higher gamma interferon levels after challenge
16. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen
17. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen
18. A Schistosoma mansoni fatty acid-binding protein, Sm14, is a potential basis of a dual-purpose anti-helminth vaccine
19. T and B epitope determination and analysis of multiple antigenic peptides for Schistosoma mansoni experimental vaccine triose-phosphate isomerase
20. Immunity and morbidity in Schistosoma mansoni infection: Quantitative aspects
21. Seeking the ghost of worms past
22. Immune responses and immunoregulation in relation to human schistosomiasis in Egypt. III. Immunity and longitudinal studies of in vitro responsiveness after treatment
23. Environmental, genetic and immunological factors in human resistance to Schistosoma mansoni
24. The human immune response to defined immunogens of Schistosoma mansoni: Elevated antibody levels to paramyosin in stool-negative individuals from two endemic areas in Brazil
25. Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for Schistosoma mansoni
26. Human immune responses to Schistosoma mansoni vaccine candidate antigens
27. Genetic control of schistosome infections by the SMI locus of the 5q31-q33 region is linked to differentiation of type 2 helper T lymphocytes
28. The science and fiction of pertussis vaccines
29. Fall-off in immunity following diphtheria revaccination - An 8 year follow-up study
30. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results
31. Human schistosomiasis: Potential consequences of vaccination
32. Mathematical models of transmission dynamics and control of schistosomiasis
33. Human schistosomiasis: Potential long-term consequences of vaccination programs
34. Heterogeneities in schistosome transmission dynamics and control
35. Effects of anti-schistosomal chemotherapy on immune responses, protection and immunity. II. Concomitant immunity and immunization with irradiated cercariae
36. Cytokine regulation of granuloma formation in schistosomiasis
37. Immunopathology of schistosomiasis: A cautionary tale of mice and men
38. Downregulation of Th1 cytokine production accompanies induction of TH2 responses by a helminth, Schistosoma mansoni
39. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni
40. + T cells in acute Schistosoma mansoni infections
41. Leukocytes of patients with Schistosoma mansoni respond with a Th2 pattern of cytokine production to mitogen or egg antigens but with a Th0 pattern to worm antigens
42. Evidence for T helper type 2 activation in human schistosomiasis
43. Cytokine production in acute versus chronic human schistosomiasis mansoni: The cross-regulatory role of interferon-gamma and interleukin-10 in the responses of peripheral blood mononuclear cells and splenocytes to parasite antigens
44. Clinical forms of human Schistosoma mansoni infection are associated with differential activation of T-cell subsets and costimulatory molecules
45. Occurrence, roles and uses of idiotypes and anti-idiotypes in parasitic diseases
46. Occurrence of a community with a high morbidity associated with Schistosoma mansoni infection regardless of low infection intensity in north-east Brazil
47. The epidemiology of morbidity of schistosomiasis
48. Association of the therapeutic activity of praziquantel with the reversal of Symmers fibrosis induced by Schistosoma mansoni
49. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: Reversibility of morbidity twenty-three months after treatment with praziquantel
50. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: Ultrasonographic assessment
51. Diagnosis of human schistosomiasis by detection of circulating cathodic antigen with a monoclonal antibody
52. Detection of circulating anodic antigen by ELISA for seroepidemiology of schistosomiasis mansoni
53. Quantitative determination of circulating soluble egg antigen in urine and serum of Schistosoma mansoni-infected individuals using a combined two-site enzyme-linked immunosorbent assay
54. Day-to-day fluctuation of schistosome circulating antigen levels in serum and urine of humans infected with Schistosoma mansoni in Burundi
55. Clinical evaluation of a recombinant hepatitis B vaccine
56. Pediatric diphtheria and tetanus toxoids-adsorbed vaccine: Immune response to the first booster following the diphtheria and tetanus toxoids vaccine primary series
57. Cytokines: Coordinators of immune and inflammatory responses
58. Intraspecimen fecal egg count variation in Schistosoma mansoni infection
59. The schistosome egg granuloma: Immunopathology in the cause of host protection or parasite survival?
60. The exploitation of host immune responses by parasites
61. Protective effect of rSm28GST-specific T cells in schistosomiasis: Role of gamma interferon
62. Anti-fecundity immunity induced in pigs vaccinated with recombinant Schistosoma japonicum 26kDa glutathione-S-transferase
63. Vaccination of sheep against Schistosoma japonicum with either glutathione S-transferase, keyhole limpet haemocyanin or the freeze/thaw schistosomula/BCG vaccine
64. A compendium of vaccine adjuvants and excipients
65. Stabilization of vaccines using trehalose (Q-T4) technology
66. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines
67. Liposome design and vaccine development
68. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
69. Structural and immunological characterization of the vaccine adjuvant QS-21
70. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin-1 in proliferative responses
71. The selective induction of different immune responses by vaccine adjuvants
72. Macrophagic myofasciitis: An emerging entity
73. Human IgE, IgG4 and resistance to reinfection with Schistosoma hematobium
74. Age-specific decrease in seroprevalence of schistosomiasis in Puerto Rico
75. The epidemiology of schistosomiasis in Egypt: Patterns of Schistosoma mansoni infection and morbidity in Kafer El-Sheikh
76. New approaches to mucosal immunization
77. Plants for delivery of edible vaccines
78. Development of orphan vaccines: An industry perspective
79. A preliminary evaluation of a recombinant circumsporozite protein vaccine against Plasmodium falciparum malaria
80. Schistosomiasis in U.S. Peace Corps Volunteers
81. Involvement of the CNS in S. 0mansoni and S. hematobium infection
82. Neurologic complications of schistosomiasis: Review of the literature and report of two cases of transverse myelitis due to S. mansoni
83. Granuloma formation around schistosome eggs as a manifestation of delayed hypersensitivity
84. Endogenous desensitization: Changing host granulomatous response to schistosome eggs at different stages of infection with Schistosoma mansoni
85. Dynamic models of schistosomiasis morbidity
86. Efficacy of an anti-pathology vaccine in murine schistosomiasis administered with and without chemotherapy
87. Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology
88. The epidemiology of schistosomiasis in Egypt: Methods, training, and quality control of clinical and ultrasound evaluations
89. Vaccination against schistosomiasis and fascioliasis with a new recombinant antigen Sm14: Potential basis of a multi-valent anti-helminth vaccine?
90. Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein
91. Can eradication of helminthic infections change the face of AIDS and tuberculosis?
92. Monitoring and safety assessment in Phase I to Phase III clinical trials
93. Developing strategies to control schistosomiasis morbidity in nonenrolled school-age children: Experience from Egypt
94. Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine
95. Some important issues in the planning of phase III HIV vaccine efficacy trials
96. Epidemiological factors in clinical trial design
97. Preparation for a pneumococcal vaccine trial in The Gambia: Individual or community randomization?
98. Decision making during a phase III randomized controlled trial